- Home
- GSM vs DNTH Comparison
GSM vs DNTH Comparison
Compare GSM & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSM
- DNTH
- Stock Information
- Founded
- GSM 2015
- DNTH 2015
- Country
- GSM United Kingdom
- DNTH United States
- Employees
- GSM N/A
- DNTH N/A
- Industry
- GSM Metal Mining
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- GSM Basic Materials
- DNTH Health Care
- Exchange
- GSM Nasdaq
- DNTH Nasdaq
- Market Cap
- GSM 842.7M
- DNTH 711.2M
- IPO Year
- GSM N/A
- DNTH N/A
- Fundamental
- Price
- GSM $3.79
- DNTH $22.90
- Analyst Decision
- GSM
- DNTH Strong Buy
- Analyst Count
- GSM 0
- DNTH 9
- Target Price
- GSM N/A
- DNTH $46.43
- AVG Volume (30 Days)
- GSM 1.2M
- DNTH 190.0K
- Earning Date
- GSM 02-19-2025
- DNTH 11-07-2024
- Dividend Yield
- GSM 1.38%
- DNTH N/A
- EPS Growth
- GSM N/A
- DNTH N/A
- EPS
- GSM 0.21
- DNTH N/A
- Revenue
- GSM $1,652,385,000.00
- DNTH $5,366,000.00
- Revenue This Year
- GSM $2.06
- DNTH $98.73
- Revenue Next Year
- GSM $6.65
- DNTH N/A
- P/E Ratio
- GSM $18.05
- DNTH N/A
- Revenue Growth
- GSM N/A
- DNTH 51.41
- 52 Week Low
- GSM $3.72
- DNTH $10.02
- 52 Week High
- GSM $6.78
- DNTH $33.77
- Technical
- Relative Strength Index (RSI)
- GSM 30.25
- DNTH 41.66
- Support Level
- GSM $4.16
- DNTH $22.35
- Resistance Level
- GSM $4.40
- DNTH $24.22
- Average True Range (ATR)
- GSM 0.15
- DNTH 1.41
- MACD
- GSM -0.05
- DNTH -0.01
- Stochastic Oscillator
- GSM 9.33
- DNTH 15.11
About GSM Ferroglobe PLC
Ferroglobe PLC provides silicon-based alloys and specialty metals. It produces silicon metal and silicon and manganese-based alloy, serving customers in the specialty chemical, aluminum, solar, steel and ductile iron foundry industries. The company's business segments include North America - Silicon; Europe - Manganese; Europe - Silicon; South Africa - Silicon and Other segments The primary raw materials company uses to produce its electrometallurgy products includes its coal and quartz mining operations and its silicon metal and ferroalloy production.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.